Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene

Severe, life-threatening adverse reactions to capecitabine sometimes occur in the treatment of solid tumors. Screening for dihydropyrimidine dehydrogenase (DPYD) deficiency is encouraged before start of treatment, but the genetic variants that are commonly analyzed often fail to explain toxicities s...

Descripción completa

Detalles Bibliográficos
Autores principales: García-González, Xandra, López-Tarruella, Sara, García, María Isabel, González-Haba, Eva, Blanco, Carolina, Salvador-Martin, Sara, Jerez, Yolanda, Thomas, Fabienne, Jarama, María, Sáez, María Sanjurjo, Martín, Miguel, López-Fernández, Luis Andrés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190816/
https://www.ncbi.nlm.nih.gov/pubmed/30349384
http://dx.doi.org/10.2147/CMAR.S174470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190816/
https://www.ncbi.nlm.nih.gov/pubmed/30349384
http://dx.doi.org/10.2147/CMAR.S174470

Ejemplares similares